Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.
Weiyang TaoArno N ConcepcionMarieke VianenAnne C A MarijnissenFloris P G J LafeberTimothy R D J RadstakeAridaman PanditPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Our findings indicate that machine learning models based on molecular signatures accurately predict response before ADA and ETN treatment, paving the path toward personalized anti-TNF treatment.